$17.13
-0.46-2.62%
最終更新: Oct 12, 7:32 PM
$17.11
-0.48-2.75%
Benzinga
Benzinga
Benzinga
火曜日, 10 13
Benzinga
© 2026 Benzinga | All Rights Reserved
Summit Therapeutics (SMMT) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.22 | $-0.23 | $-0.10 | $-0.08 |
| Actual | $-0.19 | $-0.15 | $-0.14 | $-0.13 |
| Surprise | +13.6% | +34.8% | -40.0% | -62.5% |
| Revenue | ||||
| Estimate | $88500 | $40850 | $56.8M | $56.9M |
| Actual | $0 | $0 | $0 | $0 |
| Surprise | -100.0% | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.23 | $-0.28 | $-0.28 | $-0.28 |
| Revenue | ||||
| Consensus | $54140 | $3.9M | — | — |
| 会計四半期 | 報告日 | 実質EPS | 推定EPS | 驚き ％ |
|---|---|---|---|---|
| Q2 | Jul 23, 2026 | $-0.19 | $-0.22 | 13.6 % |
| Q1 | Apr 30, 2026 | $-0.15 | $-0.23 | 34.8 % |
| Q4 | Feb 23, 2026 | $-0.14 | $-0.10 | -40.0 % |
| Q3 | Oct 20, 2025 | $-0.13 | $-0.08 | -62.5 % |
| 会計四半期 | 報告日 | 実際の収益 | 推定収益 | 驚き ％ |
|---|---|---|---|---|
| Q2 | Jul 23, 2026 | $0 | $88.50K | -100.0 % |
| Q1 | Apr 30, 2026 | $0 | $40.85K | -100.0 % |
| Q4 | Feb 23, 2026 | $0 | $56.78M | -100.0 % |
| Q3 | Oct 20, 2025 | $0 | $56.92M | -100.0 % |